Status Awaiting development
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6146

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
09 May 2024 Please note that ID6206 and ID6146 have now been combined into one appraisal. The new ID number is ID6428 'Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence' - please refer to ID6428 number for further information on these appraisals.
12 January 2024 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2024.
19 July 2023 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
01 February 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
12 December 2022 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available.

For further information on our processes and methods, please see our CHTE processes and methods manual